IL133585A0 - Soluble prodrugs of paclitaxel - Google Patents

Soluble prodrugs of paclitaxel

Info

Publication number
IL133585A0
IL133585A0 IL13358597A IL13358597A IL133585A0 IL 133585 A0 IL133585 A0 IL 133585A0 IL 13358597 A IL13358597 A IL 13358597A IL 13358597 A IL13358597 A IL 13358597A IL 133585 A0 IL133585 A0 IL 133585A0
Authority
IL
Israel
Prior art keywords
paclitaxel
onium salts
methods
novel
salts
Prior art date
Application number
IL13358597A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of IL133585A0 publication Critical patent/IL133585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13358597A 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel IL133585A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (1)

Publication Number Publication Date
IL133585A0 true IL133585A0 (en) 2001-04-30

Family

ID=22261122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13358597A IL133585A0 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Country Status (10)

Country Link
EP (1) EP1001769B1 (de)
JP (1) JP2002505682A (de)
AT (1) ATE219363T1 (de)
AU (1) AU3574097A (de)
CA (1) CA2294606A1 (de)
DE (1) DE69713526D1 (de)
HU (1) HUP0002521A3 (de)
IL (1) IL133585A0 (de)
SK (1) SK182599A3 (de)
WO (1) WO1998058927A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061141A2 (en) * 1999-04-09 2000-10-19 Au Jessie L S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002064132A2 (en) * 2001-01-18 2002-08-22 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
EP1603512A2 (de) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Neue cyclosporine
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
EP2296645B1 (de) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Antitumorale kombinationstherapie
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
KR102165464B1 (ko) 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP4303232A3 (de) 2013-02-15 2024-04-17 The Regents of The University of California Chimärer antigen-rezeptor und verfahren zur verwendung davon
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
KR102319882B1 (ko) 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
EP3377523A4 (de) 2015-11-19 2019-06-19 The Regents of The University of California Konditionell reprimierbare immunzellenrezeptoren und verfahren zur verwendung davon
EP3231421A1 (de) 2016-04-11 2017-10-18 Greenaltech, S.L. Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
SG10202107808SA (en) 2017-01-18 2021-08-30 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof
EP3388082A1 (de) 2017-04-13 2018-10-17 Galera Labs, LLC Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
MX2020008028A (es) 2018-01-31 2020-12-11 Galera Labs Llc Terapia de combinacion para cancer con complejo de anillo macrociclico de pentaaza y agente anticancer basado en platino.
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
US11897928B2 (en) 2018-07-18 2024-02-13 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
BR112021019701A2 (pt) 2019-04-02 2021-12-14 Kenjockety Biotechnology Inc Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
AU2021283080A1 (en) 2020-06-04 2022-12-15 William Robert ARATHOON ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
EP4161650A1 (de) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Anti-abcg2-antikörper und verwendungen davon
WO2022051390A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
EP4244257A1 (de) 2020-11-13 2023-09-20 Kenjockety Biotechnology, Inc. Anti-mrp4 (codiert durch abcc4-gen) antikörper und verwendungen davon
KR20230122008A (ko) 2020-11-20 2023-08-22 알.피.쉐러 테크놀러지즈 엘엘씨 항체-약물 접합체를 위한 글리코시드 이중-절단 링커
AU2022413942A1 (en) 2021-12-13 2024-05-30 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4013595A (en) * 1995-10-27 1997-05-15 Scripps Research Institute, The Method for treating cancer using taxoid onium salt prodrugs
KR100615783B1 (ko) * 1997-05-27 2006-08-25 아이박스 리서치 인코포레이티드 탁산 치료를 받고 있는 인체를 제외한 포유동물의 과민증 또는 알러지 반응을 경감시키기 위한 방법 및 약학적 키트

Also Published As

Publication number Publication date
EP1001769A4 (de) 2000-05-24
HUP0002521A2 (hu) 2001-06-28
SK182599A3 (en) 2000-07-11
CA2294606A1 (en) 1998-12-30
WO1998058927A1 (en) 1998-12-30
DE69713526D1 (de) 2002-07-25
AU3574097A (en) 1999-01-04
EP1001769B1 (de) 2002-06-19
HUP0002521A3 (en) 2002-04-29
JP2002505682A (ja) 2002-02-19
EP1001769A1 (de) 2000-05-24
ATE219363T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT68498A (en) L-dopa ester compositions and process to prepare them
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY125821A (en) Pharmaceutical composition of topiramate
DK0975595T3 (da) Kokainanaloger
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
PL342614A1 (en) Anticarcinogenic drugs
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
BG104983A (en) Aryl fused azapolycyclic compounds
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
MY126998A (en) Substituted pyrroles.
BR9714774A (pt) Pró-drogas solúveis de paclitaxel
JO2360B1 (en) Substituted pyrolates
NO996311L (no) Loeselige forlegemidler av paklitaksel
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств